{"id":"W2061399161","doi":"10.1016/j.ygyno.2005.12.020","title":"A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: A National Cancer Institute of Canada Clinical Trials Group Study","year":2006,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"Protease and Inhibitor Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":149,"is_retracted":false,"has_abstract":false,"ca_institutions":"Ontario Institute for Cancer Research; Bayer (Canada); University of Manitoba; Nova Scotia Cancer Centre; Health Sciences Centre; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Clinical endpoint; Chemotherapy; Ovarian cancer; Interim analysis; Carboplatin; Oncology; Surgery; Placebo; Gemcitabine; Cancer; Paclitaxel; Randomized controlled trial; Pathology; Cisplatin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002160487,0.002683069,0.004022511,0.0005908495,0.0005937848,0.001332358,0.001533361,0.002000443,0.007946056],"category_scores_gemma":[0.001609846,0.0009788022,0.002177511,0.0008966433,0.001979018,0.001468982,0.0005760869,0.004542602,0.001665126],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001440158,"about_ca_system_score_gemma":0.002419301,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004034715,"about_ca_topic_score_gemma":0.009031185,"domain_scores_codex":[0.9993867,0.0003058015,0.00002728452,0.0001056832,0.00003685784,0.0001376861],"domain_scores_gemma":[0.9986261,0.0002397183,0.0002910637,0.0001287064,0.00005937034,0.0006550104],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9787465,0.006129337,0.001080757,0.0001696799,0.0005882051,0.00004233207,0.00004403619,0.0003952368,0.002435081,0.00008840852,0.001171672,0.009108775],"study_design_scores_gemma":[0.953455,0.04376617,0.00164014,0.000006776955,0.0002615693,0.00003211529,0.00001803632,0.0002179156,0.000197652,0.00006466249,0.0003308424,0.000009053627],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9900153,0.00201928,0.0004225972,0.001013526,0.0004249453,0.002461185,0.001930398,0.0001516348,0.001561095],"genre_scores_gemma":[0.981089,0.002633139,0.001608346,0.001421513,0.0005245656,0.004006671,0.003828871,0.00005924692,0.004828745],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007946056,"threshold_uncertainty_score":0.02658218,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02761768728875214,"score_gpt":0.3488508885259267,"score_spread":0.3212332012371746,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}